ArticleCureus2026
A Study of Factors Associated With Melasma and Quality of Life in Patients With Melasma: A Case-Control Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Melasma is a common condition seen in dermatology clinics and is considered to be a multifactorial disease. We designed the present study to: study the factors associated with melasma (including metabolic syndrome (MetS) and biochemical parameters); compare the characteristics of melasma and other factors (MetS and biochemical parameters) in male and female melasma patients; and evaluate the quality of life in melasma patients and its correlation with the severity of the condition. Methods This study is a case-control study of 80 individuals with melasma and 80 controls attending a private dermatology clinic in Mumbai, India. We collected demographic details and other risk factors in both groups and clinical details in patients with melasma. We assessed the following biochemical parameters, such as fasting blood sugar, glycated hemoglobin (HbA1c), triglycerides, and high-density lipoproteins. In patients with melasma, severity was evaluated using the Melasma Area and Severity Index (MASI) score, and quality of life using the Melasma Quality of Life (MELASQOL) questionnaire. Results The mean (SD) age of the cases (37.2 (5.9)) was significantly higher than controls (30.6 (7.0)) years (p<0.001). A significantly higher proportion of cases had a family history (in first-degree relatives) compared with controls (52.5% (n=42) vs 16.3% (n=13); p<0.001). A lower proportion of cases were classified as MetS compared with controls; however, it was not statistically significant (30.0% (n=24) vs 33.8% (n=27); p=0.61). Although a higher proportion of females had metabolic syndrome compared with males, the difference was not statistically significant (35.2% (n=19) vs 19.2% (n=5); p=0.15). In multivariate models, melasma was significantly associated with age ≥35 years (odds ratio (OR): 4.3, 95% confidence interval (CI): 1.6, 11.4; p<0.01), being married (OR: 4.8, 95% CI: 1.1, 21.7; p<0.01), and a family history of melasma (OR: 8.1, 95% CI: 2.9, 23.1; p<0.01). Males melasma cases were more likely to have high triglyceride levels compared with females (OR: 8.6, 95% CI: 1.6, 47.5; p=0.014). Correlation between MASI and MELASQOL scores was statistically significant in females (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.